Genmab to Submit Biologics License Application to US Food and Drug Administration for Epcoritamab (DuoBody^®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B Cell Lymphoma (LBCL)

Genmab A/S announced its intent to submit a biologics license application to the FDA for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma.